Evidence map›Paper›PMID 32974892›Full record

ArticleHepatology (Baltimore, Md.)2021

Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.

John E Eaton, Christopher L Welle, Zeinab Bakhshi, Shannon P Sheedy, Ilkay S Idilman, Gregory J Gores, Charles B Rosen, Julie K Heimbach, Timucin Taner, Denise M Harnois and 5 more

Open access · greenAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Ultrasound for the Detection of Gallbladder Malignancy in Primary Sclerosing Cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Application of AI on cholangiocarcinoma.Frontiers in oncology · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Primary sclerosing cholangitis: review for radiologists.Abdominal radiology (New York) · 2023
    Review
  13. Impact on follow-up strategies in patients with primary sclerosing cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Cholangiocarcinoma.Nature reviews. Disease primers · 2021
    Review
  20. Progress toward improving outcomes in patients with cholangiocarcinoma.Current treatment options in gastroenterology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

John E EatonDivision of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN.
Christopher L WelleDepartment of Radiology, Mayo Clinic, Rochester, MN.
Zeinab BakhshiDivision of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN.
Shannon P SheedyDepartment of Radiology, Mayo Clinic, Rochester, MN.
Ilkay S IdilmanDepartment of Radiology, Mayo Clinic, Rochester, MN.
Gregory J GoresDivision of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN.
Charles B RosenDivision of Transplantation Surgery, Mayo Clinic, Rochester, MN.
Julie K HeimbachDivision of Transplantation Surgery, Mayo Clinic, Rochester, MN.
Timucin TanerDivision of Transplantation Surgery, Mayo Clinic, Rochester, MN.ORCID 0000-0003-0641-2930
Denise M HarnoisDivision of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, FL.
Keith D LindorDivision of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ.
Nicholas F LaRussoDivision of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN.
Andrea A GossardDivision of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN.
Konstantinos N LazaridisDivision of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-0437-681X
Sudhakar K VenkateshDepartment of Radiology, Mayo Clinic, Rochester, MN.
Mayo Clinic in Arizona · USJacksonville College · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
Dissecting the pathogenesis and outcomes of PSC using multi-omics by studying the exposome and genomeRC2DK118619 · NIDDK · MAYO CLINIC ROCHESTER · PI LAZARIDIS, KONSTANTINOS N · 2018 to 2022
$7.8M
Pathophysiology of Biliary DiseaseR01DK057993 · NIDDK · MAYO CLINIC ROCHESTER · PI LARUSSO, NICHOLAS F., O'HARA, STEVEN P · 2001 to 2025
$7.1M
NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK057993NIDDK NIH HHS RC2 DK118619
6 · The paper itself

Abstract

BACKGROUND AND

aimsEarly detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify more people eligible for curative therapy. While many recommend CCA screening, there are divergent opinions and limited data regarding the use of ultrasound or magnetic resonance imaging (MRI) for early CCA detection, and it is unknown whether there is benefit in testing asymptomatic individuals. Our aims were to assess the diagnostic performances and prognostic implications of ultrasound and MRI-based CCA detection. APPROACH AND

resultsThis is a multicenter review of 266 adults with PSC (CCA, n = 120) who underwent both an ultrasound and MRI within 3 months. Images were re-examined by radiologists who were blinded to the clinical information. Respectively, MRI had a higher area under the curve compared with ultrasound for CCA detection: 0.87 versus 0.70 for the entire cohort; 0.81 versus 0.59 for asymptomatic individuals; and 0.88 versus 0.71 for those listed for CCA transplant protocol. The absence of symptoms at CCA diagnosis was associated with improved 5-year outcomes including overall survival (82% vs. 46%, log-rank P < 0.01) and recurrence-free survival following liver transplant (89% vs. 65%, log-rank P = 0.04). Among those with asymptomatic CCA, MRI detection (compared with ultrasound) was associated with reduction in both mortality (hazard ratio, 0.10; 95% confidence interval, 0.01-0.96) and CCA progression after transplant listing (hazard ratio, 0.10; 95% confidence interval, 0.01-0.90). These benefits continued among patients who had annual monitoring and PSC for more than 1 year before CCA was diagnosed.

conclusionsMRI is superior to ultrasound for the detection of early-stage CCA in patients with PSC. Identification of CCA before the onset of symptoms with MRI is associated with improved outcomes.

Indexed as

AdultBile Duct NeoplasmsCholangiocarcinomaCholangitis, SclerosingEarly Detection of CancerFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedObserver VariationPrognosisSurvival AnalysisUltrasonography

Identifiers

PMID32974892
PMCPMC8177077
OpenAlexW3087956134

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.